Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry
Standard
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. / Ukena, Christian; Mahfoud, Felix; Ewen, Sebastian; Bollmann, Andreas; Hindricks, Gerhard; Hoffmann, Boris A; Linz, Dominik; Musat, Dan; Pavlicek, Valerie; Scholz, Eberhard; Thomas, Dierk; Willems, Stephan; Böhm, Michael; Steinberg, Jonathan S.
In: CLIN RES CARDIOL, Vol. 105, No. 10, 10.2016, p. 873-879.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry
AU - Ukena, Christian
AU - Mahfoud, Felix
AU - Ewen, Sebastian
AU - Bollmann, Andreas
AU - Hindricks, Gerhard
AU - Hoffmann, Boris A
AU - Linz, Dominik
AU - Musat, Dan
AU - Pavlicek, Valerie
AU - Scholz, Eberhard
AU - Thomas, Dierk
AU - Willems, Stephan
AU - Böhm, Michael
AU - Steinberg, Jonathan S
PY - 2016/10
Y1 - 2016/10
N2 - INTRODUCTION: Ventricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.METHODS: These are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1-12 months after RDN.RESULTS: Within 4 weeks prior RDN, a median of 21 (interquartile range 10-30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0-7) (p = 0.004) and 0 (p = 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.CONCLUSIONS: In patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.
AB - INTRODUCTION: Ventricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.METHODS: These are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1-12 months after RDN.RESULTS: Within 4 weeks prior RDN, a median of 21 (interquartile range 10-30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0-7) (p = 0.004) and 0 (p = 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.CONCLUSIONS: In patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.
KW - Aged
KW - Anti-Arrhythmia Agents/therapeutic use
KW - Blood Pressure
KW - Disease-Free Survival
KW - Heart Failure/complications
KW - Heart Rate/drug effects
KW - Humans
KW - Kidney/innervation
KW - Male
KW - Middle Aged
KW - Postoperative Complications/etiology
KW - Registries
KW - Sympathectomy/adverse effects
KW - Sympathetic Nervous System/physiopathology
KW - Tachycardia, Ventricular/diagnosis
KW - Time Factors
KW - Treatment Outcome
KW - Ventricular Fibrillation/diagnosis
U2 - 10.1007/s00392-016-1012-y
DO - 10.1007/s00392-016-1012-y
M3 - SCORING: Journal article
C2 - 27364940
VL - 105
SP - 873
EP - 879
JO - CLIN RES CARDIOL
JF - CLIN RES CARDIOL
SN - 1861-0684
IS - 10
ER -